[Skip to Navigation]
August 1969

Comparative Studies of Rubella Vaccines

Author Affiliations

Atlanta; Decatur, Ga; Memphis; Atlanta
From the National Communicable Disease Center, Health Services and Mental Health Administration, Public Health Services, US Department of Health, Education, and Welfare, Atlanta (Drs. Karchmer, Herrmann, Friedman, Shope, Page, and Witte); the Memphis and Shelby County Health Department, Memphis (Dr. Armes); and the Dekalb County Department of Public Health, Decatur, Ga (Dr. Dressler).

Am J Dis Child. 1969;118(2):197-202. doi:10.1001/archpedi.1969.02100040199007

IN 1966 Parkman, Meyer, and colleagues1,2 attenuated rubella virus by 77 passages in primary African green monkey kidney (GMK) cell culture and began to evaluate this strain (HPV-77) as a vaccine. Since that time, a number of attenuated rubella strains have been derived from HPV-77. Among these, three have emerged as major vaccine candidates: HPV-77 passaged five times in duck embryo fibroblast cell culture (HPV-77DE5)3,4; HPV-77 passaged 12 times in dog kidney cell culture (HPV-77DK12)5; and HPV-77 passaged three additional times in primary GMK cell culture (HPV-80) (according to a written communication from R. N. Hull, PhD, in June 1969). In addition, an attenuated strain of rubella virus (Cendehill) has been developed by 51 passages in primary rabbit kidney cell culture.6-8 Studies with these vaccines have established that they are immunogenic and attenuated when used in children, and that, although shed in the pharynx,

Add or change institution